Mantle Cell Lymphoma · line 1 · Rituximab maintenance post-induction MCL (LyMa schedule)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-RITUXIMAB-MAINTENANCE-MCL |
| ID | IND-MCL-POST-INDUCTION-RITUXIMAB-MAINTENANCE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-MCL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
Post-induction maintenance — applies after autoSCT (fit younger track) OR after BR/R-CHOP (older track). Engine should NOT activate this when 1L was BTKi-R continuous (handled by BTKi continuation). LyMa (Le Gouill 2017 NEJM) is the primary post-autoSCT evidence; EU MCL Elderly (Kluin-Nelemans 2012 NEJM) is the primary post-CIT evidence.
Used By
No reverse references found in the YAML corpus.